News

Novartis cannot block generic version of Entresto, judge rules
A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...
Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...
Drug Store News2d
U.S. federal judge rejects Novartis’ efforts to block MSN's generic Entresto
Novartis could soon face generic competition for Entresto after judge's ruling.
Novartis loses bid to block US Entresto generic through 2026
Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...
Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback
Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year ...
Fierce Pharma2d
Novartis’ Pluvicto finally picks up speed, delivers another trial win in early prostate cancer
Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...
BioSpace2d
Novartis ‘Moving as Fast as Possible’ to Fully Manufacture Key Drugs in US as Tariffs Near
In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...
Novartis AG (NVS) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic Initiatives ...
Novartis AG (NVS) reports robust sales and income growth, announces a $10 billion share buyback, and navigates competitive ...
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months to June, the company said in its second-quarter sales report. That ...
NDTV Profit on MSN5d
Divi's Labs Shares Slide After Novartis' Entresto Loses Patent Lawsuit
Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based ...